These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28614820)

  • 1. Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms.
    Falvella FS; Luoni M; Cheli S; Fava S; Cergnul M
    Chemotherapy; 2017; 62(5):323-326. PubMed ID: 28614820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
    Deenen MJ; Meulendijks D; Cats A; Sechterberger MK; Severens JL; Boot H; Smits PH; Rosing H; Mandigers CM; Soesan M; Beijnen JH; Schellens JH
    J Clin Oncol; 2016 Jan; 34(3):227-34. PubMed ID: 26573078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
    Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
    Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
    Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
    Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
    Lee AM; Shi Q; Pavey E; Alberts SR; Sargent DJ; Sinicrope FA; Berenberg JL; Goldberg RM; Diasio RB
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
    Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
    Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
    Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Ikonnikova A; Fedorinov D; Gryadunov D; Heydarov R; Lyadova M; Moskalenko A; Mikhailovich V; Emelyanova M; Lyadov V
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
    Ticha I; Kleiblova P; Fidlerova J; Novotny J; Pohlreich P; Kleibl Z
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):615-8. PubMed ID: 19288105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
    Kleibl Z; Fidlerova J; Kleiblova P; Kormunda S; Bilek M; Bouskova K; Sevcik J; Novotny J
    Neoplasma; 2009; 56(4):303-16. PubMed ID: 19473056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
    Gross E; Busse B; Riemenschneider M; Neubauer S; Seck K; Klein HG; Kiechle M; Lordick F; Meindl A
    PLoS One; 2008; 3(12):e4003. PubMed ID: 19104657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
    Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
    BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; van Werkhoven E; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Eur J Cancer; 2019 Jan; 107():60-67. PubMed ID: 30544060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
    Wigle TJ; Povitz BL; Medwid S; Teft WA; Legan RM; Lenehan J; Nevison S; Panuganty V; Keller D; Mailloux J; Siebring V; Sarma S; Choi YH; Welch S; Winquist E; Schwarz UI; Kim RB
    Clin Transl Sci; 2021 Jul; 14(4):1338-1348. PubMed ID: 33620159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Amstutz U; Froehlich TK; Largiadèr CR; Beijnen JH; de Boer A; Deenen MJ; Cats A; Schellens JH
    Int J Cancer; 2016 Jun; 138(11):2752-61. PubMed ID: 26804235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.
    Knikman JE; Zhai Q; Lunenburg CATC; Henricks LM; Böhringer S; van der Lee M; de Man FM; Offer SM; Shrestha S; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; van Schaik RHN; Gelderblom H; Mathijssen RHJ; Schellens JHM; Cats A; Guchelaar HJ; Swen JJ
    Genome Med; 2024 Aug; 16(1):101. PubMed ID: 39148102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis.
    de Moraes FCA; de Almeida Barbosa AB; Sano VKT; Kelly FA; Burbano RMR
    BMC Cancer; 2024 Sep; 24(1):1210. PubMed ID: 39350200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
    Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
    BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
    Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
    Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.